Skip to main content

Table 4 Prognostic/predictive factors at multivariate analysis

From: Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

Survival (N=136) HR 95% CI Wald-p
Age
> median 1.64 1.08-2.48 0.0199
EPHA2
High vs. Low 1.67 1.05-2.63 0.0287
EREG
High vs. Low 0.38 0.21-0.66 0.0006
AREG/KRAS interaction 7.98 2.98-21.40 <.0001
AREG high in KRAS mutant vs    
AREG high in KRAS wild type    
AREG    
AREG high vs. low for KRAS wild type 0.17 0.08-0.34 <.0001
AREG high vs. low for KRAS mutant 1.33 0.67-2.61 0.4165
KRAS    
KRAS mutant vs. wild type for AREG high 1.49 0.90-2.45 0.1184
KRAS mutant vs. wild type for AREG low 0.19 0. 08–0.43 <.0001